Physician profile
Marion E Tamesis
NPI 1821022344
$5,238.04
in general payments reported to CMS, 2019-2025
23 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $273 · 2021: $300 · 2022: $486 · 2023: $1,111 · 2024: $1,301 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.51 |
| Education | $108.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.25 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $675.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $600.75 | 2019-2025 | |
| Janssen Biotech, INC. | $508.40 | 2021-2025 | Tremfya |
| Genzyme Corporation | $453.76 | 2020-2025 | |
| Lilly USA, LLC | $435.23 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $429.22 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $275.12 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $248.49 | 2023-2025 | Sotyktu |
| Amgen INC. | $153.62 | 2023-2025 | Otezla, Otezla |
| Stemline Therapeutics INC. | $138.89 | 2021 | |
| Sun Pharmaceutical Industries INC. | $119.29 | 2020-2025 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.83 | 2023-2025 | Spevigo |
| Genentech USA, INC. | $96.69 | 2019 | |
| Organogenesis INC. | $67.20 | 2023-2024 | Puraply |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $53.35 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $51.09 | 2024-2025 | Nemluvio |
| Biofrontera INC. | $48.69 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.33 | 2020 | |
| Celgene Corporation | $20.64 | 2019 | |
| Botanix Sb INC | $16.90 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $15.52 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.77 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Tamesis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.